UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts		1-14041		04-2882273
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

400 Wood Road		02184
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

Haemonetics Corporation’s Annual Meeting of Stockholders was held on July 21, 2011. At the meeting:

1)		Lawrence C. Best, Brian Concannon, and Ronald L. Merriman were elected to serve as directors of Haemonetics;
2)		The amendment and extension of the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan were considered and approved;
3)		Advisory vote on the executive compensation program and the compensation paid to Haemonetics Corporation’s named executive officers was approved;
4)		Recommendation, by non-binding vote, to hold an advisory vote on executive compensation to occur every one (1) year was made;
5)		The selection of Ernst & Young LLP to serve as the independent registered public accounting firm of Haemonetics Corporation for fiscal year 2012 was ratified.

Below are the number of votes cast for or against, the number of abstentions, and the number of broker non-votes:

Election of Directors:

Director		Votes For				Withheld				Broker Non-Votes
Lawrence C. Best			23,328,852				323,202				776,375
Brian Concannon			23,478,871				173,183				776,375
Ronald L. Merriman			23,241,154				410,900				776,375

Amendment of long-term incentive compensation plan approval:

Votes For		Votes Against		Abstain		Broker Non-Votes
19,126,833		4,087,767		437,454		776,375

Advisory vote on executive compensation:

Votes For		Votes Against		Abstain		Broker Non-Votes
23,285,048		341,497		25,509		776,375

Frequency of advisory vote on executive compensation:

One (1) Year		Two (2) Years		Three (3) Years		Abstain		Broker Non-Votes
21,474,297		14,683		2,149,861		13,213		776,375

Ratification of auditors:

Votes For		Votes Against		Abstain
24,139,341		288,280		808

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.